Eliem Therapeutics Total Debt vs. Market Capitalization
| ELYMDelisted Stock | USD 3.23 0.01 0.31% |
For Eliem Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eliem Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eliem Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eliem Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eliem Therapeutics over time as well as its relative position and ranking within its peers.
Eliem |
Eliem Therapeutics Market Capitalization vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Eliem Therapeutics's current stock value. Our valuation model uses many indicators to compare Eliem Therapeutics value to that of its competitors to determine the firm's financial worth. Eliem Therapeutics is rated below average in total debt category among its peers. It is rated # 2 in market capitalization category among its peers creating about 981.88 of Market Capitalization per Total Debt. Comparative valuation analysis is a catch-all technique that is used if you cannot value Eliem Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Eliem Total Debt vs. Competition
Eliem Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 149 Million. Eliem Therapeutics adds roughly 349,000 in total debt claiming only tiny portion of equities under Health Care industry.
Eliem Market Capitalization vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Eliem Therapeutics |
| = | 349 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Eliem Therapeutics |
| = | 342.68 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Eliem Market Capitalization vs Competition
Eliem Therapeutics is rated # 2 in market capitalization category among its peers. Market capitalization of Health Care industry is currently estimated at about 3.46 Billion. Eliem Therapeutics holds roughly 342.68 Million in market capitalization claiming about 10% of equities under Health Care industry.
Eliem Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Eliem Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eliem Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Eliem Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Eliem Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. Eliem Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Eliem Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Eliem Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eliem Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eliem Therapeutics' important profitability drivers and their relationship over time.
Use Eliem Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eliem Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will appreciate offsetting losses from the drop in the long position's value.Eliem Therapeutics Pair Trading
Eliem Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Eliem Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eliem Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eliem Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eliem Therapeutics to buy it.
The correlation of Eliem Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eliem Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eliem Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eliem Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Eliem Therapeutics position
In addition to having Eliem Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marijuana Thematic Idea Now
Marijuana
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |